

for an association between the body burden of DDE and breast cancer risk in a population of primarily Caucasian women. For women with the highest body burdens of DDE, the risk of breast cancer was found to be four times higher than for those with the lowest burdens. In the second study (2) by Nancy Krieger and her colleagues at the Kaiser Foundation Research Institute, no association was found between DDT and breast cancer when women of all races were examined together. However, a positive association (although not statistically significant) was observed between DDT and breast cancer risk in Caucasian and African-American women. Among Asian women there was no evidence of an association.

There are several possible mechanisms by which DDT may increase risk of breast cancer. Hormonal modulation (estrogenicity and antiestrogenicity) is only one possibility. Another is induction of cytochrome P450 enzymes. These mechanisms may act independently or in concert with one another. Moreover, whatever the mechanisms of action, the carcinogenic potency of DDT and its metabolites may be enhanced by the persistence of these compounds in the human body.

To determine whether the apparent association between DDT and breast cancer risk is real, further epidemiologic investigations as well as complementary mechanistic studies must be carried out. The ultimate hope is that this research may identify a preventable environmental cause of breast cancer in women.

Mary S. Wolff

Philip J. Landrigan

Mount Sinai Medical Center,
One Gustave L. Levy Place,
New York, NY 10029-6574, USA

References

1. M. S. Wolff *et al.*, *J. Natl. Cancer Inst.* **85**, 648 (1993).
2. N. Krieger *et al.*, *ibid.* **86**, 589 (1994).

Genetic Testing and Insurance Costs

In his letter about genetic testing and the costs of insurance (9 Sept., p. 1509), J. Alexander Lowden argues that "If . . . only the applicant [can] know his or her risk and may legally conceal it from the insurer, then insurance will become too expensive for all but those who know they will succumb at an early age." The argument is specious. The cost of insuring individuals who have genetic diseases has been included in insurance costs based on actuarial tables when there was no genetic testing, and the deaths due to inherited disease were part of the age-distributed probability of death due to random-

ly experienced causes. The insurance companies did not go broke during that period, as Lowden fears could happen in the future.

If one of the insured in that distribution knows that he or she will die of a certain disease, but the insurance company doesn't, little will have been changed for the insurance company. Lowden might fear that individuals who know they will die of a certain disease, perhaps prematurely, will stock up on insurance to better provide for their heirs. However, the levels of insurance individuals buy are dictated by affordability.

Even if the relatively small fraction of the population with heritable diseases were to double the amount of life insurance they buy, there would still be a random element to the payout periods. The cause of death might be predictable, but the age of death is not, within broad limits. By excluding people who have been diagnosed as having a genetic disease, the insurance companies would shift the mean age of death in their actuarial distributions to a higher age. This will defer benefit payments and help short-term profits. Long-term profits should not be affected significantly, as most of "the rest of us [with] perfect genes" will either collect their annuities or die while insured.

S. J. Deitchman

3606 Stewart Drive,
Chevy Chase, MD 20815, USA

Children's Vaccine Initiative

The special *Science* issue "Frontiers in medicine: vaccines" (2 Sept. 1994) is an excellent and comprehensive report focusing on the high cost-effectiveness of vaccines and the need for new initiatives to bring their benefits to the children who need them most.

The News reports emphasize the need for intensified efforts to bring new research ideas to fruition in the form of vaccines against the most important diseases of the developing world, ensuring all the while that these vaccines will not be priced so high as to be unreachable for most children.

As Ann Gibbons points out (News, 2 Sept., p. 1376), the Children's Vaccine Initiative (CVI) has been slow to gain momentum. The recent reorganization in the World Health Organization (WHO) to centralize vaccine activities in the Global Programme for Vaccines and Immunization will now provide the strong leadership necessary to move ahead. The three units of the Global Programme for Vaccines and Immunization—Vaccine Research and Development, Vaccine Supply and Quality, and the Expanded Programme on Immunization—can address barriers to delivery of old vaccines

TO ANYONE WHO THINKS THAT CARBOHYDRATE
SEPARATION MIGHT HAVE
REACHED ITS PEAK.....
WELL IT HASN'T

Signal™ fluorescent labelling and GlycoSep™ HPLC columns allow cost-effective, quantitative and preparative profiling of charged and neutral glycans.

Signal™ Fluorescent Labelling

Signal™ is a simple, convenient method of fluorescent labelling a glycan pool. The technique utilizes 2-aminobenzamide (2-AB) in a validated, 2 step procedure that labels glycans efficiently (>85%) and non-selectively at the reducing terminus.

GlycoSep™ High Resolution Glycan Profiling

GlycoSep™ is an HPLC based kit that allows 2 dimensional profiling of 2-AB labelled glycans, providing reproducible, quantitative results. As no high pH conditions are used, structural integrity is assured and sample isolation and work-up is easy.

To find out how Signal™ and GlycoSep™ can extend your carbohydrate-related research, call us today.

800-722-2597



Oxford GlycoSystems Inc. Cross Island Plaza, 133-33 Brookville Boulevard, Rosedale, New York 11422 U.S.A.

**CUSTOM PEPTIDES,
LOTS OF CHOICES.
ONLY ONE STANDARD
OF QUALITY.**

Choose the purity level that best suits your research, and your budget. Pick your quantity. Name your modification. But don't look for a choice in quality from Genosys — only the best is acceptable. So every Genosys peptide is verified by both HPLC and mass spectral analysis. 100% guaranteed, from \$25 per amino acid.

In North America, call
(800) 234-5362
GENOSYS


Genosys Biotechnologies, Inc.
1442 Lake Front Circle, Suite 185
The Woodlands, TX 77380-3600
Phone: (713) 363-3693
Fax: (713) 363-2212
E-mail: 73352.1236@compuserve.com

In Europe: Genosys Biotechnologies, Inc.
Cambridge, U.K.
Phone: +44 (0) 1223 425622
Fax: +44 (0) 1223 425966
E-mail: 100140.2401@compuserve.com

In Japan: Kurabo Industries Ltd.,
Biomedical Dept. (Osaka, Japan)
Phone: 0720-20-4504
Fax: 0720-21-9641

**Don't
Drown
Your
Data.**

Water from conventional ultrapure systems can contain trace levels of ions, pyrogens, and organics that mask peaks in today's sensitive chromatography methods. Protect your data from being swamped with the Milli-Q® TOC Plus. It provides 18 megohm-cm, organic-free (<3 ppb TOC) water and comes with an integral TOC monitor — so you'll know the level of organics in the water prior to running your chromatogram. Keep your data above water with the Milli-Q TOC Plus. For more information, call 1-800-MILLIPORE, ext. 8316. In Europe, fax us at our European headquarters in Paris at 33-1-30.12.71.83.



MILLIPORE

© 1994 Millipore Corporation. Millipore Lab Catalogue on Internet. Access URL: menu and type: http://www.millipore.com

and development of new ones along the entire continuum.

The article "Bumps on the vaccine road" by Jon Cohen (p. 1371) mentions the 31 August meeting in Geneva to address the integration of CVI into WHO's new vaccine program. This meeting has taken place, and the major governance issues have been resolved. WHO can now address the CVI goals confident of the strong organizational support of virtually all the principal agencies and donors in the field of vaccinology.

One has only to read the Perspectives in the 2 September issue (p. 1381) to realize that the CVI has not stumbled. It has already had an incalculably large impact on global thinking about vaccine development. With its consolidation with the Global Programme for Vaccines and Immunization, it will achieve its goals.

J. W. Lee

*Executive Secretary,
Children's Vaccine Initiative, and Director,
Global Programme for Vaccines and
Immunization, World Health Organization,
CH-1211, Geneva 27, Switzerland*

Career "Choice"

As a regular reader of Daniel E. Koshland Jr.'s editorials, I was surprised by the insensitivity of his reference to "choice of a career" in his 23 September editorial, "Careers in science" (p. 1787).

Unfortunately, too many in the public at large are employed, by economic necessity, in a job that they neither love nor are still interested in—they're stuck in their work, but they need the money! This probably holds true for many scientists as well, though likely a far smaller proportion than in the public as a whole.

Koshland's wording is insulting (although perhaps unintentionally) to those many adults who are not as fortunate as he and I to be employed doing something they "love." It also could be misunderstood by critics of science and academe as another example of experts—in this case, Koshland—being out of touch with "real life."

Paul J. Lavrakas

*Director, Survey Laboratory,
Northwestern University,
Evanston, IL 60208-4150, USA*

Response: I am well aware that many people take careers of necessity and that many scientists are trapped in boring jobs. That should not deter beginners from trying to find a career they expect to enjoy and all from recognizing that any job, even being editor of *Science*, involves some drudgery.

—**Daniel E. Koshland Jr.**